Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma.

ABSTRACT:

SUBMITTER: Parrondo RD 

PROVIDER: S-EPMC11377826 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature